Home / Health care / Two-part Ebola vaccine may offer protection for a year against the deadly disease
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

Two-part Ebola vaccine may offer protection for a year against the deadly disease

as informed in Of the 75 participants who received the vaccine regimen, 64 remained in the study for a follow-up visit on day 360.
No serious vaccine-associated adverse events were observed, and all 64 participants maintained antibodies to Ebola virus at day 360.
An immune response was induced by the vaccine that persisted for approximately one year in volunteers according to results from the phase-1 clinical trialNew York, March 15, 2017: A two-part Ebola vaccine regimen has been found to offer protection against the deadly disease for about a year in an early human trial.
Both of the vaccines in the regimen use harmless viral vectors, or carriers, to deliver proteins of the Ebola virus, which prompt an immune response.
The researchers noted that additional research is necessary to assess the durability of immunity beyond one year and the immune response to booster doses of vaccine.

As it stated in

2-part Ebola vaccine found to be effective

That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year.
The world should be far better prepared for the next Ebola outbreak, with further promising results on Tuesday showing the potential of a long-lasting vaccine against the deadly virus.
The vaccine requires one dose to prime the immune system and a second shot to boost the body’s response.
Debating vaccine strategiesRecent progress means experts are now confident the world will not be defenceless when the next outbreak hits.
Scientists have been racing to develop vaccines for Ebola after more than 11,300 people died in West Africa’s 2013-2016 epidemic.
Two-part Ebola vaccine offers long-lasting protection

As it stated in The world should be far better prepared for the next Ebola outbreak, with further promising results on Tuesday showing the potential of a long-lasting vaccine against the deadly virus.
That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year.
The vaccine requires one dose to prime the immune system and a second shot to boost the body’s response.
Scientists have been racing to develop vaccines for Ebola after more than 11,300 people died in West Africa’s 2013-2016 epidemic.
“The persistence of vaccine-induced immunity to one year post-immunization is truly impressive,” said researcher Matthew Snape of the University of Oxford.

This content may collect you by Victoria Hunter

To follow all the new news about Vaccine

Check Also

picture.jpg

Redditch MP Rachel Maclean joins national drive to encourage the territory’s inhabitants to get their toll free influenza bullet

according to territory MP Rachel Maclean has called on Redditch inhabitants to get their toll …